WO2013090644A3 - Anticorps anti-vih ayant des puissance et étendue accrues - Google Patents

Anticorps anti-vih ayant des puissance et étendue accrues Download PDF

Info

Publication number
WO2013090644A3
WO2013090644A3 PCT/US2012/069600 US2012069600W WO2013090644A3 WO 2013090644 A3 WO2013090644 A3 WO 2013090644A3 US 2012069600 W US2012069600 W US 2012069600W WO 2013090644 A3 WO2013090644 A3 WO 2013090644A3
Authority
WO
WIPO (PCT)
Prior art keywords
breadth
increased potency
hiv antibodies
hiv
antibodies
Prior art date
Application number
PCT/US2012/069600
Other languages
English (en)
Other versions
WO2013090644A2 (fr
Inventor
Ron DISKIN
Pamela J. Bjorkman
Michel Nussenzweig
Johannes SCHEID
Original Assignee
California Institute Of Technology
The Rockfeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/558,312 external-priority patent/US9890207B2/en
Application filed by California Institute Of Technology, The Rockfeller University filed Critical California Institute Of Technology
Publication of WO2013090644A2 publication Critical patent/WO2013090644A2/fr
Publication of WO2013090644A3 publication Critical patent/WO2013090644A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Des modes de réalisation de la présente invention concernent des compositions et des procédés pour des anticorps anti-VIH (anti-site de liaison au CD4) ayant des puissance et étendue améliorées.
PCT/US2012/069600 2011-12-13 2012-12-13 Anticorps anti-vih ayant des puissance et étendue accrues WO2013090644A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161570173P 2011-12-13 2011-12-13
US61/570,173 2011-12-13
US13/558,312 2012-07-25
US13/558,312 US9890207B2 (en) 2011-07-25 2012-07-25 Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120

Publications (2)

Publication Number Publication Date
WO2013090644A2 WO2013090644A2 (fr) 2013-06-20
WO2013090644A3 true WO2013090644A3 (fr) 2013-10-10

Family

ID=48613365

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/069600 WO2013090644A2 (fr) 2011-12-13 2012-12-13 Anticorps anti-vih ayant des puissance et étendue accrues

Country Status (1)

Country Link
WO (1) WO2013090644A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10273291B2 (en) 2011-05-09 2019-04-30 Duke University Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing
WO2013192589A1 (fr) 2012-06-21 2013-12-27 California Institute Of Technology Anticorps ciblant des mutants échappés du vih
US9951118B2 (en) * 2013-08-02 2018-04-24 The Regents Of The University Of California Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
WO2015103549A1 (fr) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Anticorps neutralisants dirigés contre la env du vih-1 et leur utilisation
EP3683233A1 (fr) 2015-03-20 2020-07-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anticorps neutralisants dirigés contre gp120 et utilisation de ceux-ci
EP4011911A1 (fr) 2015-11-03 2022-06-15 The United States of America as represented by The Secretary Department of Health and Human Services Anticorps neutralisants dirigés contre la protéine gp41 du vih-1 et leur utilisation
WO2018237357A1 (fr) * 2017-06-22 2018-12-27 University Of Maryland, Baltimore Anticorps de neutralisation du vih à large spectre contre le vih
CN111971299A (zh) 2018-02-21 2020-11-20 美国政府(由卫生和人类服务部的部长所代表) HIV-1 Env的中和抗体及其用途
WO2020010107A1 (fr) 2018-07-03 2020-01-09 Gilead Sciences, Inc. Anticorps se liant spécifiquement à la gp120 du vih pd-1 et leurs methodes d'utilisation
CN114641488A (zh) * 2019-07-08 2022-06-17 加州理工学院 具有降低的多反应性的抗hiv疫苗抗体
CR20230101A (es) 2020-08-25 2023-04-28 Gilead Sciences Inc Moléculas de unión a antígeno multi- específicas contra el vih y métodos de uso
WO2023192827A1 (fr) 2022-03-26 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps bispécifiques à enveloppe du vih-1 et leur utilisation
WO2023192881A1 (fr) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisants dirigés contre la protéine d'enveloppe (env) du vih-1 et leur utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019786A1 (fr) * 1992-03-31 1993-10-14 The Public Health Research Institute Of The City Of New York, Inc. Anticorps monoclonaux fortement neutralisants et possedant une affinite importante, diriges contre le site de liaison cd-4 de la glycoproteine gp120 du virus immunodeficitaire humain
US20090053220A1 (en) * 2006-02-03 2009-02-26 Thomas Duensing Methods and compositions for the inhibition of hiv infection of t cells
WO2011038290A2 (fr) * 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisants dirigés contre le vih-1 et utilisation associée

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019786A1 (fr) * 1992-03-31 1993-10-14 The Public Health Research Institute Of The City Of New York, Inc. Anticorps monoclonaux fortement neutralisants et possedant une affinite importante, diriges contre le site de liaison cd-4 de la glycoproteine gp120 du virus immunodeficitaire humain
US20090053220A1 (en) * 2006-02-03 2009-02-26 Thomas Duensing Methods and compositions for the inhibition of hiv infection of t cells
WO2011038290A2 (fr) * 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisants dirigés contre le vih-1 et utilisation associée

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WU, XUELING ET AL.: "Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1", SCIENCE, vol. 329, no. 5993, 13 August 2010 (2010-08-13), pages 856 - 861 *
ZHOU, TONGQING ET AL.: "Structural basis for broad and potent neutralization of HIV-1 by antibody VRCO1", SCIENCE, vol. 329, no. 5993, 13 August 2010 (2010-08-13), pages 811 - 817 *

Also Published As

Publication number Publication date
WO2013090644A2 (fr) 2013-06-20

Similar Documents

Publication Publication Date Title
WO2013016468A3 (fr) Compositions et procédés permettant d'améliorer la puissance et la portée d'anticorps anti-vih
WO2013090644A3 (fr) Anticorps anti-vih ayant des puissance et étendue accrues
WO2011123489A3 (fr) Anticorps anti-cd40
PH12014501108A1 (en) Anti-il-36r antibodies
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
PH12017500864A1 (en) Anti-notch1 antibodies
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
MX362039B (es) Anticuerpos anti-il-23.
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
IN2014DN08481A (fr)
WO2012064836A9 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MX368653B (es) Anticuerpos anti-il-23p19.
WO2012107416A3 (fr) Immunothérapie améliorée
WO2013063613A3 (fr) Procédés et compositions associés à la neutralisation intracellulaire par une igg
WO2012109238A3 (fr) Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
WO2013149111A3 (fr) Anticorps anti-tlr4 et utilisations de ceux-ci
MX2013002960A (es) Composiciones de anticuerpo y metodos de uso.
WO2014068586A3 (fr) Compositions orales solides de tolvaptan
WO2012149334A3 (fr) Procédés et compositions pour préparer et utiliser des anticorps spécifiques à une conformation
WO2012128806A8 (fr) Méthodes et compositions comprenant des ligands du récepteur à l'il-7
EP2928492A4 (fr) Protéines d'enveloppe du vih-1 et leurs fragments qui possèdent des épitopes reconnus par des anticorps largement neutralisants
WO2012158493A3 (fr) Composés qui se lient au récepteur d'érythropoïétine
WO2012139074A3 (fr) Migrastatines et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12858206

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12858206

Country of ref document: EP

Kind code of ref document: A2